<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">

<channel>
<image>
<title>freepatentsonline.com</title>
<width>141</width>
<height>131</height>
<link>http://www.freepatentsonline.com/index.html</link>
<url>http://www.freepatentsonline.com/images/logo.gif</url>
</image>

<title>freepatentsonline.com: Drug, bio-affecting and body treating compositions</title>
<link>http://www.freepatentsonline.com/result.html?query_txt=ccl/424%20and%20isd/11/10/2009&amp;uspat=on</link>
<description>USPTO Class 424 Drug, bio-affecting and body treating compositions</description>
<language>en-us</language>
<lastBuildDate>Tue, 10 Nov 2009 08:53:10 EST</lastBuildDate>

<item>
<title><![CDATA[Drug delivery technology]]></title>
<link>http://www.freepatentsonline.com/7615234.html</link>
<description><![CDATA[The invention relates to a novel drug delivery technology. More particularly the invention relates to a method of delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient; to a throwaway or reusable device for delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient in a manner as set out by the method; to a pioneer projectile for use in said method; to formulations for use in said method and to an injectate comprising a pioneer projectile and formulation. It also relates to a disposable component containing either a pioneer projectile or an injectate. The invention also relates to a throwaway or reusable device for delivering at least one therapeutic compound, or a formulation comprising the at least one therapeutic compound (hereafter drug) to a patient, and a method for administering a drug to a patient using said device. It also relates to a packaged drug for use with said device.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole]]></title>
<link>http://www.freepatentsonline.com/7615238.html</link>
<description><![CDATA[The present invention relates to plasters for prophylaxis and/or treatment of a dysfunction or disorder of nails, especially onychomycosis, onychocryptosis, nail psoriasis, melanonychia striata, and onychodystrophy, the use of said plasters and methods for prophylaxis and/or treatment of a dysfunction or disorder of nails using said plasters. Said dysfunction or disorder of nails may be induced or caused by drugs, systemic diseases, chemical compounds, physical influences, fungal, yeast, or bacterial infection of the nails and/or the nail beds, or in the context of skin diseases. The plasters show good therapeutically effects on said dysfunction or disorder of nails without the need of drilling a hole into the nail and/or daily scraping of the nail. Preferred embodiments of the plasters consist of an occlusive backing layer and a layer attached to said backing layer. The layer comes in close contact with the nail and optionally with the surrounding skin. The layer is made of a adhesive, a skin and/or nail permeation enhancer, a therapeutically effective amount of sertaconazole, and suitable additives, and/or further pharmaceutically active agents.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method and composition for the control of gastrointestinal parasites in animals]]></title>
<link>http://www.freepatentsonline.com/7615240.html</link>
<description><![CDATA[The present invention provides methods and compositions for controlling gastrointestinal parasitic infections in animals. More specifically, the invention involves the use of  sericea lespedeza  ( Lespedeza cuneata ), commonly referred to as Chinese bush clover, in the diet of animals to control nematodal gastrointestinal infections.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Medical dressing for application and maintenance of medication on body tissue]]></title>
<link>http://www.freepatentsonline.com/7615236.html</link>
<description><![CDATA[A medical method and dressing for application, and maintenance of medication on healthy, damaged diseased or infected living tissue. Medication is applied to body tissue and then coated with a bioadhesive providing medication maintenance on tissue and protection from body and other liquids or abrasion thereby preventing removal of the medication during a healing or treatment process.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Tea for treating dermatitis comprising herbal extracts]]></title>
<link>http://www.freepatentsonline.com/7615239.html</link>
<description><![CDATA[Technical Field: Tea  Technical Problem: To provide a drinkable tea having a high therapeutic effect against atopic dermatitis. Means for Solving: It is characterized in that it contains extracts drawn from one, two or more medicinal herbs selected from the group consisting of Lightyellow  Sophora  Root,  Isatis  Leaf, and  Terminalia  Fruit. Atopic dermatitis can be cured by improving allergic constitution from the inside of body owing to antibacterial effect and antiviral effect of Lightyellow  Sophora  Root,  Isatis  Leaf and  Terminalia  Fruit, antiallergic effect of Lightyellow  Sophora  Root and  Isatis  Leaf, and intestinal mucosal protecting effect of  Terminalia  Fruit, or by a synergistic effect of them. In addition, the pharmacological effect in said extracts drawn from plants is enhanced, a pharmacological effects lacking in said extracts drawn from plants are added, or easiness of drinking the tea as a drinkable drug is improved and thus the therapeutic effect is improved by adding one, two or more auxiliary materials selected from the group of Japanese  Angelica  Root,  Oldenlandia diffusa ,  Smilax Glarba , Dried Tangerine Peel, Wild  Chrysanthemum  Flower,  Corydalis , Peppermint, Baikal Skullcap,  Lithospermum ,  Kudingcha , Smartweed, and Licorice to the extracts drawn from plants. Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Film-shaped or wafer-shaped pharmaceutical preparation with masked taste]]></title>
<link>http://www.freepatentsonline.com/7615235.html</link>
<description><![CDATA[The invention relates to thin film-shaped or wafer-shaped pharmaceutical preparations for oral administration of active substances. The preparations contain at least one matrix-forming polymer which has at least one active substance and at least one carbon dioxide-forming substance dissolved or dispersed therein.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging]]></title>
<link>http://www.freepatentsonline.com/7615208.html</link>
<description><![CDATA[The invention provides, in a general sense, a new labeling strategy employing  99m Tc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to  99m Tc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia]]></title>
<link>http://www.freepatentsonline.com/7615219.html</link>
<description><![CDATA[The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Selected immunoconjugates for binding to aminophospholipids]]></title>
<link>http://www.freepatentsonline.com/7615223.html</link>
<description><![CDATA[Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant]]></title>
<link>http://www.freepatentsonline.com/7615226.html</link>
<description><![CDATA[A method of preparing a vaccine formulation comprising at least one antigen and at least one adjuvant is described, which method is characterized in that at least one antigen is mixed with at least one adjuvant and the mixture subsequently is heat-treated at a temperature of at least 80° C. for a period of time of at least 5 minutes.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions of NDV and methods of use thereof for treatment of cancer]]></title>
<link>http://www.freepatentsonline.com/7615209.html</link>
<description><![CDATA[The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the NDV HUJ. The methods of the present invention are particularly useful for inducing regression of tumors in patients unresponsive to conventional anti-cancer therapies.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and methods for treating cancer]]></title>
<link>http://www.freepatentsonline.com/7615221.html</link>
<description><![CDATA[The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CD70 inhibition for the treatment and prevention of inflammatory bowel disease]]></title>
<link>http://www.freepatentsonline.com/7615211.html</link>
<description><![CDATA[Substantially purified populations of APC LP  cells capable of expressing CD70 are described. Also described are methods for the treatment of certain diseases and medical conditions of the gastrointestinal tract, such as inflammatory bowel disease, by utilizing inhibitors of CD70 activity.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Artificial proteins with reduced immunogenicity]]></title>
<link>http://www.freepatentsonline.com/7615217.html</link>
<description><![CDATA[The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen]]></title>
<link>http://www.freepatentsonline.com/7615225.html</link>
<description><![CDATA[The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Use of CpG oligodeoxynucleotides to induce angiogenesis]]></title>
<link>http://www.freepatentsonline.com/7615227.html</link>
<description><![CDATA[This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for enhancing the morphology, tone, texture and/or appearance of skin or hair using a meadowlactone]]></title>
<link>http://www.freepatentsonline.com/7615231.html</link>
<description><![CDATA[The present invention provides inexpensive, safe and reliable methods for improving the morphology, tone, texture and/or appearance of the skin and/or hair of a mammal, preferably without using one or more surfactants (or other chemicals) that can strip away, or otherwise remove, one or more protective lipids from the skin and/or hair. These methods comprise topically applying to the skin and/or hair at least three applications on a regular basis of a composition in an effective amount including: (a) a Meadowlactone in an amount that is effective for enhancing the morphology, tone, texture and/or appearance of the skin and/or hair, and having the chemical structure set forth herein; and (b) a cosmetically acceptable base in an amount that is effective for acting as a carrier vehicle for the Meadowlactone.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Particulate construct comprising polyhydroxyalkanoate and method for producing it]]></title>
<link>http://www.freepatentsonline.com/7615233.html</link>
<description><![CDATA[The invention provides a particulate construct comprising a polyhydroxyalkanoate to serve as microcapsules containing a drug, and serving a slow releasing preparation not associated with a practically unacceptable initial burst release but showing a practically acceptable zero-order release for a certain period and a producing method for such particulate construct, and a slow releasing preparation of a high drug content capable of stably incorporating the drug in the particulate construct such as microcapsules, and a producing method for such preparation.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Mutants of the P4 protein of nontypable <i>Haemophilus influenzae </i>with reduced enzymatic activity]]></title>
<link>http://www.freepatentsonline.com/7615229.html</link>
<description><![CDATA[A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable  H. influenzae  (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nucleic acid-lipophilic conjugates]]></title>
<link>http://www.freepatentsonline.com/7615539.html</link>
<description><![CDATA[The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby]]></title>
<link>http://www.freepatentsonline.com/7615616.html</link>
<description><![CDATA[A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®—like characteristics from Gram positive bacteria, such as  Enterococcus, Staphylococcus, Streptococcus  and  Bacillus  bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[<i>Bacillus amyloliquefaciens </i>KTGB0202 and control method of plant pathogenic fungi using that]]></title>
<link>http://www.freepatentsonline.com/7615366.html</link>
<description><![CDATA[The present invention relates to a novel microorganism  Bacillus amyloliquefaciens  KTGB0202 and a method for controlling plant pathogens using the same. More particularly, the present invention relates to a novel microorganism  Bacillus amyloliquefaciens  KTGB0202 (accession number: KCTC 10564BP) bacterium which has an excellent control effect against crop powdery mildew and a broad spectrum of antifungal activity against plant pathogenic fungi and inhibits tobacco mosaic virus infection, as well as an eco-friendly bacterial culture broth for controlling powdery mildew, which contains the same. Also, the present invention relates to antifungal substance KTGB0202AFO1 obtained by extraction and purification from the  Bacillus amyloliquefaciens  KTGB0202 bacteria. The inventive  Bacillus amyloliquefaciens  KTGB0202 bacteria have a broad spectrum of antifungal activity, and are excellent in activity continuance and used for controlling various plant pathogens, including powdery mildew.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Granulates containing liposoluble substances and a process for the preparation thereof]]></title>
<link>http://www.freepatentsonline.com/7615547.html</link>
<description><![CDATA[A process is described for the preparation of granulates that contain liposoluble and hydrophobic substances, preferably steroidal substances, and that exhibit rapid and excellent water-dispersibility. The process comprises:
 
     a) the dispersion of substance (A) in water in the presence of a surfactant (B), b) the incorporation of a water-soluble polyhydroxylated solid excipient (C) in the aqueous dispersion until a granulable pasty mass is obtained and c) the granulation of the mass. 
     
  The granulates so obtained are suitable for the preparation, at the time of use, of stable and homogeneous aqueous suspensions that are used for nutritional, cosmetic or, preferably, pharmaceutical purposes.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodies]]></title>
<link>http://www.freepatentsonline.com/7615383.html</link>
<description><![CDATA[The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[High affinity human antibodies to human IL-18 receptor]]></title>
<link>http://www.freepatentsonline.com/7615220.html</link>
<description><![CDATA[An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18Rα), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Treatment and prevention of tissue damage]]></title>
<link>http://www.freepatentsonline.com/7615543.html</link>
<description><![CDATA[An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Treatment of endometriosis]]></title>
<link>http://www.freepatentsonline.com/7615210.html</link>
<description><![CDATA[A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual that includes administering to the individual at least one agent that reduces the effect of prokineticin 1 on a prokineticin receptor.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Polypeptide fragments of hepatitis E virus, the vaccine comprising said fragments and the diagnostic kits]]></title>
<link>http://www.freepatentsonline.com/7615228.html</link>
<description><![CDATA[A purified polypeptide comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of a polymer with n monomeric polypeptides, wherein n is an integer from 2-180; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention. The present invention further relates to a vaccine composition against hepatitis E virus which comprises the above-mentioned polypeptide, or diagnostic kit for hepatitis E virus infection comprising the above-mentioned polypeptide, which includes IgG, IgM, or total antibody diagnostic kit for hepatitis E virus, and to the use of vaccine composition and diagnostic kit for prophylaxis, diagnosis and/or treatment of hepatitis E virus infection.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method for decreasing sebum production]]></title>
<link>http://www.freepatentsonline.com/7615230.html</link>
<description><![CDATA[The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for treating irritable bowel syndrome]]></title>
<link>http://www.freepatentsonline.com/7615207.html</link>
<description><![CDATA[Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Anti-human VEGF receptor Flt-1 monoclonal antibody]]></title>
<link>http://www.freepatentsonline.com/7615214.html</link>
<description><![CDATA[The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Multiplex-bead complex for determination of lysosomal storage disorders]]></title>
<link>http://www.freepatentsonline.com/7615224.html</link>
<description><![CDATA[Multiplexing bead technology is used for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Diagnostic compositions include microspheres conjugated to purified antibodies that specifically bind LSD target antigens: saposin, LAMP-1, α-iduronidase, α-glucosidase, β-glucosidase, 2-sulphatase, 4-sulphatase, α-galactosidase, sphingomyelinase, 3-sulphatase or sulphamidase. The target antigens are naturally present in biological fluids or tissues of either LSD or non-LSD patients.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Percutaneously absorbable preparations]]></title>
<link>http://www.freepatentsonline.com/7615237.html</link>
<description><![CDATA[Percutaneously absorbable preparations (preferably nonaqueous ones, particularly matrix-type patches or ointment), containing salt-form acidic drugs and characterized by being improved in the percutaneous absorbability of the drug by the incorporation of an addition salt of a basic substance therewith and by being lowly irritant to the skin; and a percutaneous absorption accelerator for salt-form acidic drugs, containing an addition salt of a basic substance.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Antibodies against human interleukin-13 and pharmaceutical compositions thereof]]></title>
<link>http://www.freepatentsonline.com/7615213.html</link>
<description><![CDATA[This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Antibodies against CCR5 and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7615216.html</link>
<description><![CDATA[Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same]]></title>
<link>http://www.freepatentsonline.com/7615222.html</link>
<description><![CDATA[The disclosed technology provides an enriched antibody population, highly specific for an antigen of a surface polysaccharide, from a mycobacterium. In a related embodiment, the antibody is enriched by having been raised in an environment that maintains antigenically active antigen. These antibodies may be used in an immunoreactive environment for detecting the presence of a mycobacterial infection in a sample from a subject.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Anti-human VEGF receptor Flt-1 monoclonal antibody]]></title>
<link>http://www.freepatentsonline.com/7615215.html</link>
<description><![CDATA[The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for determining and lowering caffeine concentration in fluids]]></title>
<link>http://www.freepatentsonline.com/7615218.html</link>
<description><![CDATA[Single-chain, camelized heavy chain antibodies immunospecific for caffeine and stable at high temperatures are useful for analysis and recovery of caffeine in or from fluids. A device that provides a single-step lateral flow assay for caffeine and a useful peptide spacer are also described.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compounds and methods for promoting smoking cessation]]></title>
<link>http://www.freepatentsonline.com/7615567.html</link>
<description><![CDATA[Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Modified interferon beta with reduced immunogenicity]]></title>
<link>http://www.freepatentsonline.com/7615615.html</link>
<description><![CDATA[The present invention relates a modified human interferon beta (INFβ) which is less immunogenic than human INFβ (SEQ ID NO: 1) when administered in vivo to a human. The modified human INFβ comprises an amino acid residue sequence that differs from SEQ ID NO: 1 by an amino acid residue substitution selected from the group consisting of L57A, L57C, L57D L57E, L57G, L57H, L57K, L57N, L57P, L57Q, L57R, L57S, and L57T and an additional substitution selected from the group consisting of the H140A, H140C, H140G, and H140P.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Bifunctional-modified hydrogels]]></title>
<link>http://www.freepatentsonline.com/7615593.html</link>
<description><![CDATA[Disclosed are hydrogels wherein a polymer matrix is modified to contain a bifunctional poly(alkylene glycol) molecule covalently bonded to the polymer matrix. The hydrogels can be cross-linked using, for example, glutaraldehyde. The hydrogels may also be crosslinked via an interpenetrating network of a photopolymerizable acrylates. The hydrogels may also be modified to have pharmacologically-active agents covalently bonded to the poly(alkylene glycol) molecules or entrained within the hydrogel. Living cells may also be entrained within the hydrogels.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use]]></title>
<link>http://www.freepatentsonline.com/7615359.html</link>
<description><![CDATA[The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Antibodies with immune effector activity and that internalize in endosialin-positive cells]]></title>
<link>http://www.freepatentsonline.com/7615372.html</link>
<description><![CDATA[This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Dental self-etching primer]]></title>
<link>http://www.freepatentsonline.com/7614879.html</link>
<description><![CDATA[Bond strength of a composite resin, an adhesive resin cement or the like to dentin or enamel of tooth is remarkably improved by treating the dentin or the enamel with a self-etching primer agent comprising an aqueous solution of a methacrylic acid derivative such as N-methacryloylglycin, N-methacryloyl-3-aminopropionic acid, N-methacryloyl-4-aminobutyric acid, N-methacryloyl-5-aminovaleric acid, N-methacryloyl-6-aminocaproic acid, N-methacryloyl-2-aminomethylphosphonic acid, N-methacryloyl-3-aminoethyl-phosphonic acid and N-methacryloyl-4-aminopropylphosphonic acid.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and methods for the systemic treatment of arthritis]]></title>
<link>http://www.freepatentsonline.com/7615212.html</link>
<description><![CDATA[The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[System to monitor the ingestion of medicines]]></title>
<link>http://www.freepatentsonline.com/7616111.html</link>
<description><![CDATA[A system for monitoring ingestion of medicine ( 21 ) comprises forming a digestible radio frequency identification (RFID) tag ( 10 ). The RFID tag is attached to the medicine. The RFID tag and medicine are ingested. A signal from the RFID tag is monitored.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Surfactant/solvent systems]]></title>
<link>http://www.freepatentsonline.com/7615232.html</link>
<description><![CDATA[The present invention relates to surfactant/solvent systems for liquid formulations comprising
 α) one or more nonaromatic-based surfactants, β) as solvent, one or more triester(s) of phosphoric acid with alcohols, preferably from the group consisting of
     1) monohydric alkanols having 5 to 22 carbon atoms, for example with n-, i- or neo-pentanol, n-hexanol, n-octanol, 2-ethylhexanol, 2) diols or polyols, such as ethylene glycol, propylene glycol or glycerol, 3) aryl, alkylaryl, poly(alkyl)aryl and poly(arylalkyl)aryl alcohols, for example with phenol and/or cresol, octylphenol, nonylphenol, triisobutylphenol, tristyrylphenol, 4) alkoxylated alcohols obtained by reacting the alcohols mentioned above under 1), 2) or 3) with alkylene oxides, preferably (C 1 -C 4 )alkylene oxides, and 5) alkoxylated alcohols obtained by reacting monohydric alkanols having 1 to 4 carbon atoms and alkylene oxides.
 
The surfactant/solvent system according to the invention is suitable for the preparation of liquid active substance formulations.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Expression and use of novel pesticidal toxins]]></title>
<link>http://www.freepatentsonline.com/7615686.html</link>
<description><![CDATA[A novel pesticidal toxin isolated from  Bacillus thuringiensis  that is highly active against a wide range of lepidopteran insect pests is disclosed. The DNA encoding the pesticidal toxin can be used to transform various prokaryotic and eukaryotic organisms to express the pesticidal toxin. These recombinant organisms can be used to control lepidopteran insects in various environments.]]></description>
<pubDate>Tue, 10 Nov 2009 08:00:00 EST</pubDate>
</item>

</channel>
</rss>
